APA (7th ed.) Citation

T, E., M, S., T, G., V, K., PG, T., ES, P., . . . AG, K. (2019). How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview. Advances in therapy, 36(7), 1532. https://doi.org/10.1007/s12325-019-00971-0

Chicago Style (17th ed.) Citation

T, Empeslidis, Storey M, Giannopoulos T, Konidaris V, Tranos PG, Panagiotou ES, Voudouragkaki IC, and Konstas AG. "How Successful Is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview." Advances in Therapy 36, no. 7 (2019): 1532. https://doi.org/10.1007/s12325-019-00971-0.

MLA (9th ed.) Citation

T, Empeslidis, et al. "How Successful Is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview." Advances in Therapy, vol. 36, no. 7, 2019, p. 1532, https://doi.org/10.1007/s12325-019-00971-0.